Skip to main content
Clinical Trials/EUCTR2006-003391-35-NL
EUCTR2006-003391-35-NL
Active, not recruiting
Not Applicable

Evaluation of the efficacy and safety of unpreserved dexamethasone phosphate 0.1% eye drops (T1910) versus placebo in patients with bilateral treated severe keratoconjunctivitis sicca due to Sjögrens' syndrome

aboratoires THEA0 sitesJuly 5, 2006

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
keratoconjunctivitis sicca
Sponsor
aboratoires THEA
Status
Active, not recruiting
Last Updated
14 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 5, 2006
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
aboratoires THEA

Eligibility Criteria

Inclusion Criteria

  • 1\.Male or female aged from 18 to 75 years old.
  • 2\.Primary or secondary Sjögren:
  • ØAlready diagnosed by the rheumatologist and the maxillofacial specialist.
  • ØFulfilling the European criteria (Vitali et al 1996\)
  • 3\.Severe dry eye syndrome in BOTH EYES defined by:
  • \-Questioning on patient’s feeling: score \= 3\.
  • \-At least two of the following ocular symptoms suggestive of dry eye: burning, stinging, dryness feeling, sandy and/or gritty sensation, light sensitivity, reflex tearing, ocular fatigue, blurred vision (improved by tears substitute).
  • \-Schirmer test \< 5 mm in 5 min OR BUT \< 7 s.
  • \-Keratoconjunctivitis defined by a lissamine green score (Van Bijsterveld score) \= 4
  • Are the trial subjects under 18? no

Exclusion Criteria

  • 1\.Dry eye syndrome primarily related to inflammation of ocular surface
  • 2\. Contraindications to topic dexamethasone :Glaucoma, IOP steroid responder, Herpes simplex, vaccinia, varicella zoster and most other viral infections of the cornea and conjunctiva, bacterial infections, all lesions with involvement of the corneal epithelium, Tuberculosis, fungal infections, acute purulent infections, which like other diseases caused by micro\-organisms, can be masked or aggravated by the presence of steroids
  • 3\.Eyelid dysfunction : Eyelid malposition, Blepharospasm, Facial paralysis, Severe ocular progressive rosacea/ severe blepharitis
  • 4\.History WITHIN THE LAST 3 MONTHS before the inclusion visit of : Traumatism, Infection (Viral conjunctivitis / Bacterial conjunctivitis / Staphylococcal blepharitis)
  • 5\.Any relevant ocular anomaly interfering with ocular surface: chemical burns, corneal distrophy, orbital radiotherapy, etc…….
  • 6\.Known history of ocular allergy.
  • 7\. Best corrected far visual acuity (VA) \= 1/10\.

Outcomes

Primary Outcomes

Not specified

Similar Trials